Microsurgical Reconstruction of the Jaws Using Vascularised Free Flap Technique in Patients with Medication-Related Osteonecrosis: A Systematic Review
Table 2
Main antiangiogenic drugs used (IV: intravenous; MM: multiple myeloma; PO: orally; SC: subcutaneous; Btl: bottle; Tab: tablet).
Pharmacologic active ingredient
Formulation
Route of administration
Indication and frequency
Bevacizumab
Btl 400 mg Btl 100 mg
IV
Metastatic breast cancer (10 mg/kg every 2 weeks or 15 mg/kg every 3 weeks); colorectal cancer (5 mg/kg or 10 mg/kg every 2 weeks); lung/ovarian cancer (7.5 mg/kg or 15 mg/kg every 3 weeks); renal cell cancer (10 mg/kg every 2 weeks); glioblastoma (10 mg/kg every 2 weeks)
Sunitinib
Tab 12.5 mg
PO
Renal cell cancer, GISTs and neuroendocrine tumors (50 mg/day for 4 weeks)
Sorafenib
Tab 200 mg
PO
Renal cell cancer (800 mg/day)
Pazopanib
Tab 200 mg Tab 400 mg
PO
Renal cell cancer (200–800 mg/day)
Thalidomide
Tab 50 mg
PO
Myeloma (400 mg/day for 6 weeks)
Lenalidomide
Tab 5, 10, 15 and 25 mg
PO
Myeloma (tailored doses)
Everolimus
Tab 5 and 10 mg
PO
Renal cell cancer, breast cancer (10 mg every day)
